Inhibition of toll-like receptor-mediated inflammation in vitro and in vivo by a novel benzoxaboroles

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 436-446

  Dong, Chen ^a   Sexton, Holly ^a   Gertrudes, Ana ^a   Akama, Tsutomu ^a   Martin, Shamra ^a   Virtucio, Charlotte ^a   Chen, Chiao Wen ^a   Fan, Xiaoqin ^a   Wu, Anne ^a   Bu, Wei ^a   Liu, Liang ^a   Feng, Lisa ^a   Jarnagin, Kurt ^a   Freund, Yvonne R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 [4 (AMINOMETHYL) 2 CHLOROPHENOXY]BENZO[C] [1,2] OXABOROL 1 (3H) OL; AN 3485; ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CD3 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; ROFLUMILAST; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CELL ISOLATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTACT DERMATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; EAR EDEMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SKIN PENETRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DERMATITIS, ALLERGIC CONTACT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; TOLL-LIKE RECEPTORS;

EID: 84872746198     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.200030     Document Type: Article

References (99)

1. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, and Plattner JJ (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19:2129-2132.
2. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, and Ciliberto G (1998) Interleukin 6 is required for the development of collageninduced arthritis. J Exp Med 187:461-4678.
3. Baker SJ, Tomsho JW, and Benkovic SJ (2011) Boron-containing inhibitors of synthetases. Chem Soc Rev 40:4279-4285.
4. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, and Edwards CK, 3rd (2000) Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 43: 2648-2659. (Pubitemid 32001730)
5. Bousquet J, Chiron R, and Humbert M (2008) Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther 8:1921-19278.
6. Carrasco S, Neves FS, Fonseca MH, Gonçalves CR, Saad CG, Sampaio-Barros PD, and Goldenstein-Schainberg C (2011) Toll-like receptor (TLR) 2 is upregulated on peripheral blood monocytes of patients with psoriatic arthritis: a role for a grampositive inflammatory trigger? Clin Exp Rheumatol 29:958-962.
7. Carta S, Tassi S, Pettinati I, Delfino L, Dinarello CA, and Rubartelli A (2011) The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering. J Biol Chem 286:27069-27080.
8. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, and McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624. (Pubitemid 34214243)
9. De Vry CG, Valdez M, Lazarov M, Muhr E, Buelow R, Fong T, and Iyer S (2005) Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 125:473-481.
10. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
11. Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC, and Morton DL (1989) Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med 170:321-326. (Pubitemid 19179717)
12. Evans DP, Hossack M, and Thomson DS (1971) Inhibition of contact sensitivity in the mouse by topical application of corticosteroids. Br J Pharmacol 43:403-4078.
13. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, and Becker C (2007) In vitro generation of CD41 CD251 regulatory cells from murine naive T cells. Nat Protoc 2:1789-1794.
14. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, and Favata MF, et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298-5307.
15. Gaestel M, Kotlyarov A, and Kracht M (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8:480-499.
16. Gozzi P, Påhlman I, Palmér L, Grönberg A, and Persson S (1999) Pharmacokineticpharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. J Pharmacol Exp Ther 291:199-203. (Pubitemid 29451591)
17. Han J, Brown T, and Beutler B (1990) Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171:465-475. (Pubitemid 20059041)
18. Han J and Ulevitch RJ (2005) Limiting inflammatory responses during activation of innate immunity. Nat Immunol 6:1198-1205. (Pubitemid 43045628)
19. Hennessy EJ, Parker AE, and O'Neill LA (2010) Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9:293-307.
20. Huang QQ and Pope RM (2009) The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 11:357-364.
21. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, and Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a triacylated lipopeptide. Cell 130:1071-1082. (Pubitemid 47410281)
22. Jin MS and Lee JO (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182-191.
23. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, and van Den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049-5055. (Pubitemid 29501273)
24. Kawai T and Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384.
25. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, and Yoo OJ, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917. (Pubitemid 47332573)
26. Kopf M, Bachmann MF, and Marsland BJ (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9:703-7178.
27. Kuchera S, Barth H, Jacobson P, Metz A, Schaechtele C, and Schrier D (1993) Antiinflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino) propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H- pyrrole-2,5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model. Agents Actions 39 (Spec No): C169-C173. (Pubitemid 23276761)
28. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, and Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19:4311-4323. (Pubitemid 29242006)
29. Lai Y and Gallo RL (2008) Toll-like receptors in skin infections and inflammatory diseases. Infect Disord Drug Targets 8:144-155.
30. Lee WY, Lockniskar MF, and Fischer SM (1994) Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J 8: 1081-1087.
31. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, and Gottlieb AB; Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022. (Pubitemid 37448924)
32. Li X, Zhang YK, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, and Fan D, et al. (2010) Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 20: 3550-3556.
33. Lindstrom TM and Robinson WH (2010) A multitude of kinases - which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 36:367-383.
34. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, and Davies DR (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320:379-381. (Pubitemid 351555661)
35. Loiarro M, Ruggiero V, and Sette C (2010) Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm 2010:674363.
36. Ma H, Deacon S, and Horiuchi K (2008) The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 3:607-621. (Pubitemid 351890673)
37. MacKenzie S, Fernàndez-Troy N, and Espel E (2002) Post-transcriptional regulation of TNF-alpha during in vitro differentiation of human monocytes/macrophages in primary culture. J Leukoc Biol 71:1026-1032.
38. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823-835. (Pubitemid 44631651)
39. Miller LS (2008) Toll-like receptors in skin. Adv Dermatol 24:71-87.
40. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, and Devesa I, et al. (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113:2324-2335.
41. O'Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3:396-403. (Pubitemid 36913535)
42. Park BS, Song DH, Kim HM, Choi BS, Lee H, and Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
43. Piccinini AM and Midwood KS (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm DOI: 10.1155/2010/672395 [published ahead of print].
44. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, and Galanos C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-20878.
45. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang YK, Hernandez V, Akama T, and Baker SJ, et al. (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316: 1759-1761. (Pubitemid 46988553)
46. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, and Plattner JJ (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 19:2129-2132.
47. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, and Ciliberto G (1998) Interleukin 6 is required for the development of collageninduced arthritis. J Exp Med 187:461-4678.
48. Baker SJ, Tomsho JW, and Benkovic SJ (2011) Boron-containing inhibitors of synthetases. Chem Soc Rev 40:4279-4285.
49. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, and Edwards CK, 3rd (2000) Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 43: 2648-2659. (Pubitemid 32001730)
50. Bousquet J, Chiron R, and Humbert M (2008) Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther 8:1921-19278.
51. Carrasco S, Neves FS, Fonseca MH, Gonçalves CR, Saad CG, Sampaio-Barros PD, and Goldenstein-Schainberg C (2011) Toll-like receptor (TLR) 2 is upregulated on peripheral blood monocytes of patients with psoriatic arthritis: a role for a grampositive inflammatory trigger? Clin Exp Rheumatol 29:958-962.
52. Carta S, Tassi S, Pettinati I, Delfino L, Dinarello CA, and Rubartelli A (2011) The rate of interleukin-1beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering. J Biol Chem 286:27069-27080.
53. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, and McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614-624. (Pubitemid 34214243)
54. De Vry CG, Valdez M, Lazarov M, Muhr E, Buelow R, Fong T, and Iyer S (2005) Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 125:473-481.
55. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550.
56. Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC, and Morton DL (1989) Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med 170:321-326. (Pubitemid 19179717)
57. Evans DP, Hossack M, and Thomson DS (1971) Inhibition of contact sensitivity in the mouse by topical application of corticosteroids. Br J Pharmacol 43:403-4078.
58. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, and Becker C (2007) In vitro generation of CD41 CD251 regulatory cells from murine naive T cells. Nat Protoc 2:1789-1794.
59. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, and Favata MF, et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298-5307.
60. Gaestel M, Kotlyarov A, and Kracht M (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8:480-499.
61. Gozzi P, Påhlman I, Palmér L, Grönberg A, and Persson S (1999) Pharmacokineticpharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. J Pharmacol Exp Ther 291:199-203. (Pubitemid 29451591)
62. Han J, Brown T, and Beutler B (1990) Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171:465-475. (Pubitemid 20059041)
63. Han J and Ulevitch RJ (2005) Limiting inflammatory responses during activation of innate immunity. Nat Immunol 6:1198-1205. (Pubitemid 43045628)
64. Hennessy EJ, Parker AE, and O'Neill LA (2010) Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9:293-307.
65. Huang QQ and Pope RM (2009) The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep 11:357-364.
66. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, and Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a triacylated lipopeptide. Cell 130:1071-1082. (Pubitemid 47410281)
67. Jin MS and Lee JO (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182-191.
68. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, and van Den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163:5049-5055. (Pubitemid 29501273)
69. Kawai T and Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384.
70. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, and Yoo OJ, et al. (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917. (Pubitemid 47332573)
71. Kopf M, Bachmann MF, and Marsland BJ (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9:703-7178.
72. Kuchera S, Barth H, Jacobson P, Metz A, Schaechtele C, and Schrier D (1993) Antiinflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino) propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H- pyrrole-2,5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model. Agents Actions 39 (Spec No): C169-C173. (Pubitemid 23276761)
73. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, and Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19:4311-4323. (Pubitemid 29242006)
74. Lai Y and Gallo RL (2008) Toll-like receptors in skin infections and inflammatory diseases. Infect Disord Drug Targets 8:144-155.
75. Lee WY, Lockniskar MF, and Fischer SM (1994) Interleukin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. FASEB J 8: 1081-1087.
76. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, and Gottlieb AB; Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022. (Pubitemid 37448924)
77. Li X, Zhang YK, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, and Fan D, et al. (2010) Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 20: 3550-3556.
78. Lindstrom TM and Robinson WH (2010) A multitude of kinases - which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am 36:367-383.
79. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, and Davies DR (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320:379-381. (Pubitemid 351555661)
80. Loiarro M, Ruggiero V, and Sette C (2010) Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm 2010:674363.
81. Ma H, Deacon S, and Horiuchi K (2008) The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 3:607-621. (Pubitemid 351890673)
82. MacKenzie S, Fernàndez-Troy N, and Espel E (2002) Post-transcriptional regulation of TNF-alpha during in vitro differentiation of human monocytes/macrophages in primary culture. J Leukoc Biol 71:1026-1032.
83. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823-835. (Pubitemid 44631651)
84. Miller LS (2008) Toll-like receptors in skin. Adv Dermatol 24:71-87.
85. Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, and Devesa I, et al. (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113:2324-2335.
86. O'Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3:396-403. (Pubitemid 36913535)
87. Park BS, Song DH, Kim HM, Choi BS, Lee H, and Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458: 1191-1195.
88. Piccinini AM and Midwood KS (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm DOI: 10.1155/2010/672395 [published ahead of print].
89. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, and Galanos C, et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-20878.
90. Rock FL, Mao W, Yaremchuk A, Tukalo M, Crépin T, Zhou H, Zhang YK, Hernandez V, Akama T, and Baker SJ, et al. (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 316: 1759-1761. (Pubitemid 46988553)
91. AN3485 Inhibits TLR-Mediated Inflammation In Vitro and In Vivo 445 Downloaded from jpet.aspetjournals.org at Elsevier Science Inc, Bibliographic Databases on January 21, 2013
92. Ruggiero V, D'Urso CM, Albertoni C, Campo S, Foresta P, and Martelli EA (1993) LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. Mediators Inflamm 2:S43-S50. (Pubitemid 23324384)
93. Shear NH (2006) Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability? Drug Saf 29:49-66. (Pubitemid 43213895)
94. Stuart JM, Watson WC, and Kang AH (1988) Collagen autoimmunity and arthritis. FASEB J 2:2950-2956. (Pubitemid 18261413)
95. Tak PP and Kalden JR (2011) Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 13 (Suppl 1):S5.
96. Xu Z, Dziarski R, Wang Q, Swartz K, Sakamoto KM, and Gupta D (2001) Bacterial peptidoglycan-induced tnf-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappaB. J Immunol 167:6975-6982. (Pubitemid 33144192)
97. Yao J, Mackman N, Edgington TS, and Fan ST (1997) Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem 272: 17795-17801. (Pubitemid 27311220)
98. Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, and Wilson IA (2012) Structural basis of TLR5-flagellin recognition and signaling. Science 335: 859-864.
99. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, and Doberstein SK, et al. (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179:1872-1883.